SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

544

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

March 30, 2026

Conditions

Heart Failure AcuteDiabetes Type 2Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction

Interventions

DRUG

Dapagliflozin tablet

Dapagliflozin 10 mg 1 tablet once daily

DRUG

Hypertonic Saline Solution, 1 Ml

Intravenous infusion of furosemide combined with hypertonic saline solutions (100 mL) twice daily

DRUG

Furosemide Injection

Furosemide 20 mg

All Listed Sponsors

lead

University of Palermo

OTHER

NCT06442280 - SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF | Biotech Hunter | Biotech Hunter